8DTO image
Entry Detail
PDB ID:
8DTO
EMDB ID:
Title:
Vaccine elicited Antibody MU89 bound to CH848.D949.10.17_N133D_N138T.DS.SOSIP.664 HIV-1 Env trimer
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2022-07-26
Release Date:
2023-04-19
Method Details:
Experimental Method:
Resolution:
3.57 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:CH848.3.D0949.10.17chim.6R.DS.SOSIP.664_N133D_N138T gp120
Mutations:N133D, N138T
Chain IDs:A (auth: E), E (auth: A), I
Chain Length:487
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:Envelope Glycoprotein gp141
Chain IDs:B (auth: F), F (auth: B), J
Chain Length:153
Number of Molecules:3
Biological Source:Human immunodeficiency virus
Polymer Type:polypeptide(L)
Description:MU89 Heavy Chain
Chain IDs:C (auth: G), G (auth: C), K
Chain Length:126
Number of Molecules:3
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:MU89 Light Chain
Chain IDs:D (auth: H), H (auth: D), L
Chain Length:106
Number of Molecules:3
Biological Source:Mus musculus
Ligand Molecules
Primary Citation

Abstact

A major goal of HIV-1 vaccine development is the induction of broadly neutralizing antibodies (bnAbs). Although success has been achieved in initiating bnAb B cell lineages, design of boosting immunogens that select for bnAb B cell receptors with improbable mutations required for bnAb affinity maturation remains difficult. Here, we demonstrate a process for designing boosting immunogens for a V3-glycan bnAb B cell lineage. The immunogens induced affinity-matured antibodies by selecting for functional improbable mutations in bnAb precursor knockin mice. Moreover, we show similar success in prime and boosting with nucleoside-modified mRNA-encoded HIV-1 envelope trimer immunogens, with improved selection by mRNA immunogens of improbable mutations required for bnAb binding to key envelope glycans. These results demonstrate the ability of both protein and mRNA prime-boost immunogens for selection of rare B cell lineage intermediates with neutralizing breadth after bnAb precursor expansion, a key proof of concept and milestone toward development of an HIV-1 vaccine.

Legend

Protein

Chemical

Disease

Primary Citation of related structures